Objective: To compare transplant outcomes among elderly (aged ≥60 years) and nonelderly recipients, and to evaluate the acceptability of elderly living donor kidney transplantation in practice after consideration of living donor type. Methods: We included 830 adult patients with living donor kidney transplantation between 2000 and 2011 in this retrospective cohort study. We compared deathcensored graft survival, patient survival, biopsy-proven rejection, complications, and renal function in elderly (n = 119) and non-elderly recipients (n = 278). Results: There was no significant difference in 10-year death-censored graft survival (P = 0.980). Corresponding patient survival rates in the elderly and non-elderly groups were 84.1% and 98.1%, respectively (hazard ratio 6.15, 95% confidence interval 2.12-17.82, P < 0.001). Elderly patients had more complications and chronic T-cell-mediated rejection. Factors associated with death in elderly recipients with functioning grafts were residual advanced recipient age (hazard ratio 1.39), decreased hemoglobin (hazard ratio 4.10), hepatitis B virus (hazard ratio 7.89), hepatitis C virus (hazard ratio 13.12) and elevated alanine aminotransferase (hazard ratio 1.13). Conclusions: Elderly living donor kidney transplantation seems to provide adequate acceptable outcomes. However, physicians should be cautious when evaluating elderly patients with hepatitis, and further studies are required to improve long-term outcomes.
Introduction
KT is the treatment of choice for most patients with ESRD. KT is associated with a decreased risk of mortality compared with maintenance dialysis, regardless of recipient age. 1 Nevertheless, there is a great disparity between organ demand and supply worldwide. In particular, elderly patients requiring KT are continuously increasing in many counrties. 2 Elderly patients waiting for KT are the fastest growing population, raising concerns regarding this issue. 2, 3 LDKT is associated with superior outcomes compared with DDKT; 4 thus, transplant communities have recommend LDKT. 5 In LDKT, donor type has the potential to generate heterogeneous stratums related to differences between recipient and donor age. In other words, a pediatric recipient is unexceptionally younger than a biological parent donor; a recipient received sibling, partner, friend or coworker donations needs to be of similar age; and an elderly recipient from a more aged biological parent donor would have an extremely low likelihood. Although a wide variety of donor types are used in LDKT, details of the donor type have not often been taken into account when evaluating elderly KT research. Most studies have compared non-elderly and elderly groups simply using "related" and "unrelated" as confounding factors without in-depth consideration. However, these comparisons might be susceptible to an important confounding bias or incorrect adjustment. 6 When evaluating transplant outcomes in elderly LDKT, recognizing the limitations inherent to each donor type might be important and informative for developing strategies to improve LDKT promotion.
Accordingly, in the present study, we aimed to clarify the degree of increase in recipient age, and the relationship between recipient and donor age by donor type; to compare clinical features, comorbidities, BPR, death-censored graft survival, and patient survival in elderly and nonelderly recipients; to determine factors associated with DWFG among the elderly population; and to clarify the acceptability of elderly LDKT in practice after consideration of donor type.
Methods

Study overview and population
We extracted data from the JACK study (Clinical Trials Registry Number: UMIN000018327). The objectives and detailed immunosuppressive regimens have been described elsewhere. 7 The study flow diagram is shown in Figure 1 . We included adults (aged ≥18 years) that underwent LDKT between 2000 and 2011. Our analyses were as follows. First, the trend in recipient age, and the relationship between the recipient and donor age by donor type were analyzed using data from 830 patients. Transplant outcomes were analyzed using populations comprising recipients with sibling and spousal donors (n = 397). Elderly recipients were defined as being aged ≥60 years (≥75th percentile, 278 non-elderly vs 119 elderly patients). We then explored which factors had deleterious effects on patient survival in the elderly population (n = 119).
End-points and follow up
The end-points included death-censored graft survival and patient survival, 8 BPR, sepsis, hepatic disorder, PTDM, malignancy, CVD, CMV, pneumonia and renal function assessed by the eGFR. BPR was defined according to the Banff 2013 classification. 9 CMV infection included the presence of CMV in plasma by pp65 antigenemia, and clinical signs and symptoms attributable to CMV infection. PTDM (new-onset diabetes after KT) was defined in accordance with the American Diabetes Association. 10 CVD included coronary artery disease, heart failure, stroke, arrhythmia and related vascular diseases. Diagnosis of CVD was recorded on medical charts by cardiologists at each center. Then each CVD was classified according to the International Classification of Diseases 10th revision. The HBV infection was defined according to hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody and HBV DNA test at KT. The occult HBV infection, refers to the presence of HBV DNA in the absence of detectable hepatitis B surface antigen, was defined as HBV-positive. Diagnosis of HCV infection was based on a HCV antibody test and a HCV RNA test. The eGFR was calculated using a Japanese modified equation. 11 The final follow up was carried out on 31 March 2016; patients whose follow-up periods exceeded 10 years had their data censored at 10 years. The mean follow-up duration was 7.5 AE 2.5 years.
Statistical analysis
Analyses were carried out using SAS version 9.4 TS1M3 (SAS Institute, Cary, NC, USA). Data are presented as means with standard deviations or medians with interquartile ranges. Graft and patient survival were estimated using the Kaplan-Meier method. HRs were calculated by conventional and non-proportional Cox mode. ORs were estimated using a logistic model. Between-group comparisons were carried out with Student's ttests, Mann-Whitney U-tests, v 2 -tests or Fisher's exact tests when appropriate. Trend tests for continuous age and dichotomous age were analyzed using linear regression model and Cochran-Armitage tests for trend, respectively. Relationships between recipient age and donor age according to donor type were assessed by analysis of covariance (ANCOVA). Two-tailed P-values of <0.05 were considered statistically significant. All analyses were carried out by an independent statistical data center (STATZ Institute, Tokyo, Japan). trend in recipient age relation of recipient and donor age by donor type Excluded (n = 433) -parents donors (n = 420) -children donors (n = 13) Fig. 1 Flow diagram. Trends in recipient age over time and relationships between recipient and donor ages by donor type were analyzed using the entire population (n = 830). Transplant outcomes were analyzed using the population with sibling and spousal donors (n = 397). Elderly recipients (n = 119) were defined as aged ≥60 years (≥75th percentile, the fourth quartile). We explored which factors had deleterious effects to reduce patient survival in the elderly population (n = 119). Recipient and donor ages by donor type Figure 3 shows the relationship between recipient age and donor age according to donor type. Three heterogeneous populations were established, and varied markedly according to donor type (P < 0.001). Substantial correlations between recipient age and donor age were observed in each cluster of donor type: child (r = 0.68), spouse (r = 0.85), sibling (r = 0.88) and parents (r = 0.84). In these populations, recipients receiving donations from siblings and spouses had similar distributions.
Results
Trends in recipient age
Characteristics of patients according to recipient age
Of the 830 patients, we excluded significantly heterogeneous populations with child and parent donors. Characteristics of 397 recipients, including sibling or spousal donors, according to recipient age are summarized in Table 1 . Elderly recipients were more likely to be male, have diabetic nephropathy and nephrosclerotic etiology, and have a CVD history. Regarding donor characteristics, elderly recipients were more likely to undergo transplant with donations from women, those with increased age and spouses compared with non-elderly patients. For the regimen of immunosuppressants, elderly the proportion of the variance in recipient age that is predictable from donor age. P-value from ANCOVA denotes differences in intercept terms in each linear regression model.
patients were more likely to receive basiliximab and rituximab, but were less likely to have pre-existing donor-specific anti-HLA antibodies (P = 0.012). Figure 4a shows Kaplan-Meier estimates for death-censored graft survival (n = 397 recipients). There were no significant differences between the two groups, and the HR of the elderly group was 1.01 (P = 0.980). Figure 4b shows the patient survival curves. The 10-year rates in the non-elderly and elderly groups were 98.1% (95% CI 96.5-99.8) and 84.1% (95% CI 73.9-94.2), respectively. The HR of the elderly group was 6.15 (P < 0.001); elderly recipients were inferior to non-elderly recipients, and the hazardous probability of DWFG increased during the late study period. Causes of graft failure and patient death, BPRs, major complications and renal function are also listed in Table 2 . Compared with the non-elderly group, the elderly group had more complications. Notably, the ORs of elderly LDKT recipients for chronic TCMR and sepsis were 4.28 (P = 0.013) and 7.33 (P = 0.016). When evaluating graft loss (non-censored for death), the proportions of graft loss caused by DWFG were 61% and 20% in the elderly and non-elderly groups, respectively.
Transplant outcomes
Potential factors associated with DWFG in elderly patients
We explored which factors had deleterious effects on patient survival among the elderly population (n = 119). Adjusted HRs of potential risk factors are shown in Table 3 . Residual advancing recipient age, decreased hemoglobin, HBV positivity, HCV positivity and elevated ALT were identified as factors associated with an increased risk of DWFG. We also carried out sensitivity analysis using another variable selection approach. Sensitivity analysis did not change the results.
Discussion
In the present study, we showed that the mean age of Japanese recipients increased over time, and nearly 25% of patients were aged >60 years in 2010-2011. The relationship between recipient and donor age varied dramatically with donor type. Elderly recipients had inferior patient survival and more complications than younger patients. Notably, viral hepatitis was associated with an increased risk of DWFG among the elderly population. However, elderly LDKT patients had similar graft survival compared with younger patients, and an excellent 10-year patient survival of 84.1%.
In the present study, we applied a restriction approach rather than a multivariable adjustment approach to donor type in order to evaluate the effects of recipient age on transplant outcomes. 6 Relationships between recipient and donor age varied markedly with donor type. In our experience, we have never seen a recipient older than 60 years with their parent donation. If such a case existed, the donor age would be near 90 years. Additionally, elderly patients who are aware of their limited life expectancy tend to be reluctant to receive a donation from their child, and we as clinicians are also not very willing to recommend child donations because of ethical and logical considerations. As a result, in the present study, we essentially compared "older-for-older" with "young-foryoung" transplants. 12, 13 We assumed that most aging subgroups in LDKT were recipients with nearly the same aged donors; for example, siblings, spouses, friends and others with social connections worldwide. There was no difference in death-censored graft survival rates between the non-elderly and elderly groups. Fritsche et al. showed a strong relationship with the degree of HLA mismatches and acute rejection in elderly recipients with DDKT.
14 However, this imbalance did not rise in the present study. The post-transplant eGFR in the elderly group was lower than that in the non-elderly group throughout the study; this result is expected, because the eGFR formula accounts for aging. Relative to the non-elderly group, the elderly group had higher rates of life-threatening sepsis and complications, including hepatic conditions, PTDM, malignancy and CVD. The present results were similar to those of past studies. 15 Notably, higher chronic TCMR was observed in the elderly group. In general, antibody-mediated rejection is a major concern during the later period after KT. Aging can affect cell-mediated immunity, and the mechanisms of rejection can differ between non-elderly and elderly recipients. 2 However, it is unclear whether changes in immunity with age contribute to the observed high risk of chronic TCMR or whether this result occurred by chance in the present study. Further studies are required to confirm these findings.
Not surprisingly, the elderly group showed inferior patient survival compared with the non-elderly group; particularly late follow-up period. DWFG was the dominant cause of graft loss (non-censored for death) in the elderly group (61%). In a previous study, age-matching of donors and recipients did not result in improved outcomes. 16 Although elderly patients showed obviously worse survival rates compared with young patients, the 10-year elderly patient survival rate (84.1%) was excellent. Furthermore, previous studies have shown that KT for elderly patients can confer a significant reduction in mortality compared with dialysis. 1, 17 In addition, Hourmant et al. reviewed several recent important studies with large cohorts of living kidney donors including elderly individuals, and concluded that kidney transplantation from an elderly living donor appeared to be a reasonably safe procedure for both the donor and the recipient, and the age per se was certainly not a contraindication to donation. 18 These results suggested that patient age might be a surrogate for other health and functional issues. 2, 15 The present results also supported that advanced age in patients with ESRD should not be considered a contraindication or barrier to LDKT. In an analysis restricted to elderly patients, we found the viral hepatitis had a negative impact on long-term patient survival. We included inactive HBV carrier and occult HBV infection as HBV-positive, because this condition often leads to reactivation of the virus under immunosuppressive therapy. HCV had a greater influence than HBV. This result might reflect the evolution of HCV into a chronic condition. Odds ratios were obtained by logistic regression model. Post-transplant diabetes mellitus excluded pre-existing diabetes. Virus-activated CD4 helper T cells have a role in HCVassociated liver injury, stimulating HCV-specific CD8 cytotoxic T cells through induction of cytokines. Fabrizi et al.
showed that HBV-and HCV-positive patients have lower patient and graft survival than negative recipients in largescale meta-analyses. 19 More recently, Goodkin et al. found that the prevalence of HCV is 7.5%, and that HCV is associated with a higher risk of death and anemic complications; furthermore, HCV is almost never treated in patients on dialysis based on The Dialysis Outcomes and Practice Patterns Study. 20 Today, the advent of DAAs has revolutionized the treatment of HCV. Although there is currently limited evidence regarding the treatment of HCV with DAA after KT, the early or perioperative treatment with DAAs could potentially reduce the risk of HCV-related complications in even elderly recipients. 21, 22 Thus, elderly recipients should be screened aggressively for liver conditions both pre-and post-transplant. 23 There were several limitations in the present study. First, precise information on the antiviral treatment of hepatitis was lacking. Second, our study did not have adequate power to investigate whether hepatitis had additive or synergistic deleterious effects on DWFG among elderly patients. Also, the elderly population required more basiliximab and rituximab. The contributions of these agents to hepatitis are unclear. Further large-scale studies are required to obtain robust evidence regarding the interactions among residual advanced recipient age, immunosuppressants and hepatitis in elderly LDKT. Finally, we recognize recipient age of ≥60 years might be slightly young to be categorized as elderly. We intended to define elderly as septuagenarians. However, this definition had to be changed, because there were just six septuagenarians (Fig. 3) . In Japan, living organ donations are restricted to certain related or in-law donors based on a legal standpoint. Under these circumstances, LDKT for very elderly patients is unlikely to occur. Thus, the present findings should be interpreted with caution regarding the generalizability and comparisons with studies carried out in other programs. 24 Nevertheless, we believe the present findings could aid in the development of programs for elderly LDKT patients. 2, 25 In conclusion, elderly LDKT from siblings and spousal donors was associated with a 10-year patient survival of 84.1%. The present study showed that chronological age was not a major risk factor or barrier to LDKT. Our findings supported that "old-for-old" LDKT could provide adequate acceptable transplant outcomes. However, physicians should be cautious when elderly patients have hepatitis, and further studies are required to determine whether appropriate management of hepatitis including DAAs use for elderly patients would improve their long-term outcomes.
